A randomised phase II trial comparing the efficacy of single fraction or multi-fraction SABR (Stereotactic ablative body radiotherapy) with AteZolizumab in patients with advanced Triple nEgative breast Cancer
Primary Sponsor
Victorian Comprehensive Cancer Centre (VCCC)
Collaborating Groups
Trans Tasman Radiation Oncology Group (TROG)
Accrual Target
32
Final Accrual
32
Closing Date of Accrual
22 November 2022
Trial Chairperson
Dr Steven David, Peter MacCallum Cancer Centre, VIC
Related Post
8 July, 2025
Recruitment Milestone Achieved for TROG 19.06 DECREASE Trial
TRIAL UPDATE: 8 July 2025 The TROG 19.06 DECREASE
26 June, 2025
Cancer Survivor to Take on Fifth Kokoda trek to Support TROG
LATEST NEWS: 26 June 2025 He may be 76
